InvestSMART

BARD1 Life Sciences Limited (ASX: BD1) - Announcements

Current share price for BD1 : $1.035 0.01 (0.98%)+

ASX company news and announcements for BARD1 Life Sciences Limited (BD1) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BARD1 Life Sciences Limited (BD1) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BARD1 Life Sciences Limited (BD1), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BARD1 Life Sciences Limited (BD1)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- Final Director's Interest Notice - Dr Irminger-Finger 15 Jan 2021 2:34PM $0.640 $1.035 risen by 61.72%
- Dr Irminger steps down from Board, continues as Consultant 15 Jan 2021 9:43AM $0.605 $1.035 risen by 71.07%
- Change of Director's Interest Notice - Cumming 8 Dec 2020 10:08AM $0.790 $1.035 risen by 31.01%
- Change of Director's Interest Notice - Powell 3 Dec 2020 9:48AM $0.700 $1.035 risen by 47.86%
- Change of Director's Interest Notice - Johnston 3 Dec 2020 9:47AM $0.700 $1.035 risen by 47.86%
- Final Director's Interest Notice - Helen Fisher 2 Dec 2020 3:48PM $0.690 $1.035 risen by 50%
- Patent Granted in China for hTERT 2 Dec 2020 9:47AM $0.022 $1.035 risen by 4,604.55%
- Further Detail on BARD1's US Sales Strategy 1 Dec 2020 6:03PM $0.022 $1.035 risen by 4,604.55%
- Trading Halt 1 Dec 2020 10:05AM $0.022 $1.035 risen by 4,604.55%
- Pause in Trading 1 Dec 2020 9:57AM $0.022 $1.035 risen by 4,604.55%
- Results of Meeting 27 Nov 2020 8:27AM $0.023 $1.035 risen by 4,400%
- AGM & CEO Presentations and Chairman's Transcript 26 Nov 2020 4:04PM $0.023 $1.035 risen by 4,400%
- Consolidation/Split - BD1 26 Nov 2020 10:29AM $0.023 $1.035 risen by 4,400%
- Helen Fisher Steps Down from BARD1 Board 25 Nov 2020 1:24PM $0.025 $1.035 risen by 4,040%
- BARD1 Gains New High-volume Customer for its hTERT Test 23 Nov 2020 9:36AM $0.025 $1.035 risen by 4,040%
- Appendix 4C and Quarterly Activities Report 30 Oct 2020 4:34PM $0.025 $1.035 risen by 4,040%
- Notice of Annual General Meeting/Proxy Form 27 Oct 2020 1:37PM $0.026 $1.035 risen by 3,880.77%
- Notice of AGM ASX Listing Rule 3.13.1 19 Oct 2020 4:54PM $0.025 $1.035 risen by 4,040%
- Successful BARD1 Kit Evaluation 23 Sep 2020 9:01AM $0.027 $1.035 risen by 3,733.33%
- BARD1 Awarded BTB Funding to Develop Breast Cancer Test 3 Sep 2020 9:10AM $0.028 $1.035 risen by 3,596.43%
- Revised Securities Trading Policy 31 Aug 2020 3:09PM $0.028 $1.035 risen by 3,596.43%
- Appendix 4G and Corporate Governance Statement 25 Aug 2020 7:58AM $0.030 $1.035 risen by 3,350%
- Appendix 4E and Annual Report to Shareholders 25 Aug 2020 7:58AM $0.030 $1.035 risen by 3,350%
- Change of Director's Interest - Helen Fisher 24 Aug 2020 5:01PM $0.030 $1.035 risen by 3,350%
- Change of Director's Interest - Dr Geoffrey Cumming 24 Aug 2020 5:00PM $0.030 $1.035 risen by 3,350%

76 - 100 of 309 results

Page 4 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.